Antibodies co-invented by Scripps Research and IAVI developed as a potential COVID-19 therapy
On Aug. 27, 2020, immunologists at Scripps Research, in partnership with colleagues at the IAVI Neutralizing Antibody Center,…
Bayer acquired Asklepios BioPharmaceutical for $40 billion
On Oct. 26, 2020, Bayer announced the acquisition of Asklepios BioPharmaceutical, a North Carolina-headquartered biopharmaceutical company specialized in…
ContraFect initiated expanded access to Exebacase for treatment of MRSA bloodstream infections in COVID-19 patients
On Oct. 26, 2020, ContraFect announced that it had initiated an expanded access program to provide exebacase for…
Taconic Biosciences launched critical model for COVID-19 research
On Oct. 26, 2020, Taconic Biosciences announced immediate humanized ACE2 mouse model availability for COVID-19 research. The SARS-CoV-2…
Entos Pharma awarded $5 million in NRC IRAP funding to conduct phase I Clinical trial of COVID-19 DNA vaccine
On Oct. 23, 2020, Entos Pharmaceuticals announced it was receiving advisory services and funding of up to $5…
Global clinical trials of COVID-19 vaccine resumed
On Oct. 23, 2020, the U.S. FDA authorised a restart of clinical trials of the ChAdOx1 nCov-2019 Oxford…
CureVac reported positive preclinical data for its COVID-19 vaccine candidate CVnCoV
On Oct. 23, 2020, CureVac announced data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV, in…
FDA authorised restart of the COVID-19 AZD1222 vaccine US phase III trial
On Oct. 23, 2020, AstraZeneca announced that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, had…
Johnson & Johnson prepared to resume phase 3 ENSEMBLE trial of COVID-19 vaccine candidate in the US
On Oct. 23, 2020, Johnson & Johnson announced that it was preparing to resume recruitment in the pivotal…
Landmark study 31/A5349 on the treatment of drug-susceptible TB
On Oct. 22, 2020, the World Health Organizationﾒs Global TB Programme welcomed the results from a landmark study…
Roche announced collaboration with Atea Pharmaceuticals to develop potential oral treatment for COVID-19 patients
On Oct. 22, 2020, Roche and Atea Pharmaceuticals announced they had joined forces in the fight against COVID-19…
Scientists used gene therapy and a novel light-sensing protein to restore vision in mice
On Oct. 22, 2020, a newly developed light-sensing protein called the MCO1 opsin restored vision in blind mice…
WHO and Wikimedia Foundation expanded access to trusted information about COVID-19 on Wikipedia
On Oct. 22, 2020, the World Health Organization (WHO) and the Wikimedia Foundation announced a collaboration to expand…
IAVI, Merck, and Serum Institute joined forces to develop monoclonal antibodies for COVID-19
On Oct. 22, 2020, IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges,…
Vacaville unveiled California Biomanufacturing Center and next generation of biotech development
On Oct. 22, 2020, the City of Vacaville announced the start of the next generation of development of…
Todos Medical announced distribution agreement with Adial Pharma to market Assure/FaStep Covid-19 antibody tests
On Oct. 22, 2020, Todos Medical announced that it had entered into an exclusive supply agreement with U.S….
FDA approved first treatment for COVID-19
On Oct. 22, 2020, the FDA approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric…
Landmark TB trial identified shorter-course treatment regimen
On Oct. 21, 2020, results from an international, randomized, controlled clinical trial indicated that a four-month daily treatment…
ImmunityBio, NantKwest announced first patient dosed in phase 1 clinical trial of second-generation COVID-19 vaccine candidate
On Oct. 21, 2020, ImmunityBio and NantKwest announced that the first patient had been dosed in the Phase…
Merck announced positive topline results from phase 3 adult studies evaluating V114 15-valent pneumococcal conjugate vaccine
On Oct. 20, 2020, Merck announced findings from two additional Phase 3 studies evaluating the safety, tolerability and…
Final report confirmed remdesivir benefits for COVID-19
On Oct. 20, 2020, the NIH announced that the researchers had completed the Adaptive COVID-19 Treatment Trial (ACTT-1),…
PerkinElmer immunoassay identiied therapeutic compounds capable of disrupting the SARS-CoV-2 spike protein/ACE2 interaction
On Oct. 20, 2020, PerkinElmer announced that a research team at the National Center for Advancing Translational Sciences…
BioMedomics’ COVID-19 IgM/IgG Rapid Test approved by INVIMA in Colombia
On Oct. 20, 2020, BioMedomics announced that the National Institute for Food and Drug Surveillance (INVIMA) had provided…
European Investment Bank provided Immunic with ﾀ245 million to support development of COVID-19 therapy
On Oct. 20, 2020, the European Investment Bank (EIB) and Immunic announced the signing of a ﾀ24.5 million…
Study discovered gene that helps us know when itﾒs time to urinate
On Oct. 19, 2020, researchers annoounced they had discovered that a gene, called PIEZO2, may be responsible for…
Bio-Techne announced commercial release of SARS-CoV-2 multi-antigen serology assay kit for simple western
On Oct. 19, 2020, Bio-Techne announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module for…
LabCorp and Swedish extended laboratory services relationship providing access to COVID-19 testing and diagnostics
On Oct. 19, 2020, LabCorp and Swedish, the largest nonprofit healthcare system in the Puget Sound region, announced…
LabCorp launched quantitative antibody test to assess effectiveness ef COVID-19 vaccines in clinical trials
On Oct. 19, 2020, LabCorp announced a test that provided a quantitative measurement of an individualﾒs SARS-CoV-2 IgG…
Atossa Therapeutics completed enrollment of phase 1 clinical study of AT-301 Coronavirus nasal spray
On Oct. 19, 2020, Atossa Therapeutics announced it had completed enrollment in its Phase 1 clinical study using…
NIH began large clinical trial to test immune modulators for treatment of COVID-19
On Oct. 16, 2020, the NIH launched an adaptive Phase 3 clinical trial to evaluate the safety and…